Assessment of the immunomodulatory effects of rituximab in seropositive rheumatoid arthritis using arthroscopic synovial biopsies.

Trial Profile

Assessment of the immunomodulatory effects of rituximab in seropositive rheumatoid arthritis using arthroscopic synovial biopsies.

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Nov 2014

At a glance

  • Drugs Rituximab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Pharmacodynamics
  • Acronyms ARISE
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Mar 2010 Primary endpoint identified as histopathology of synovium, Actual initiation date (Jun 2008) added, Actual patient number (24) added as reported by ClinicalTrials.gov.
    • 09 Mar 2010 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top